Chugai Pharmaceutical Co., Ltd. Share Price & Technical Analysis
CHGCY · $23.81 (-6.07%)
Healthcare / Drug Manufacturers - General
$23.81
-6.07%
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal a…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-7% return in May, -1% avg return in past 3 year May month.
4% return in 2026, 34% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 8% | 18% | -15% | 0% | -7% | – | – | – | – | – | – | – | 4% |
| 25 | -5% | 16% | -11% | 31% | -7% | -7% | -8% | -10% | 1% | -3% | 21% | 1% | 19% |
| 24 | 0% | 12% | -9% | -16% | -1% | 13% | 27% | 14% | 3% | 1% | -3% | 2% | 43% |
| 23 | -2% | -5% | 1% | 7% | 5% | 3% | 3% | 2% | 3% | 1% | 15% | 5% | 39% |
| 22 | -3% | 6% | 4% | -7% | -8% | -7% | 12% | -9% | -5% | -6% | 16% | -2% | -10% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$80.35B
P/E ratio
29.06
52W high
$34.84
52W low
$19.50
Volume
7,154
Beta
0.56
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Chugai Pharmaceutical Co., Ltd. share price today?
- Chugai Pharmaceutical Co., Ltd. (CHGCY) last traded around $23.81 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CHGCY have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CHGCY. Download the app for real-time alerts.
- How can I analyze Chugai Pharmaceutical Co., Ltd. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.